U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H43NO5
Molecular Weight 449.6233
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of URSODEOXYCHOLYLGLYCINE

SMILES

[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(=O)NCC(O)=O

InChI

InChIKey=GHCZAUBVMUEKKP-XROMFQGDSA-N
InChI=1S/C26H43NO5/c1-15(4-7-22(30)27-14-23(31)32)18-5-6-19-24-20(9-11-26(18,19)3)25(2)10-8-17(28)12-16(25)13-21(24)29/h15-21,24,28-29H,4-14H2,1-3H3,(H,27,30)(H,31,32)/t15-,16+,17-,18-,19+,20+,21+,24+,25+,26-/m1/s1

HIDE SMILES / InChI
Molecular Formula C26H43NO5
Molecular Weight 449.6233
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
PubMed

PubMed

TitleDatePubMed
Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter.
1998 Jan
Bilirubin injury to neurons: contribution of oxidative stress and rescue by glycoursodeoxycholic acid.
2008 Mar
Patents

Patents

20010024658
2
20020012680
32
JP2002537317A
97
JP4790123B2
46
JPH09315979A
2
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:30:00 GMT 2023
Edited
by admin
on Sat Dec 16 09:30:00 GMT 2023
Record UNII
PF1G5J2X2A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
URSODEOXYCHOLYLGLYCINE
Common Name English
3.ALPHA.,7.BETA.-DIHYDROXY-5.BETA.-CHOLANOYLGLYCINE
Systematic Name English
N-((3.ALPHA.,5.BETA.,7.BETA.)-3,7-DIHYDROXY-24-OXOCHOLAN-24-YL)GLYCINE
Systematic Name English
GLYCOURSODEOXYCHOLIC ACID
Common Name English
N-(3.ALPHA.,7.BETA.-DIHYDROXY-5.BETA.-CHOLAN-24-OYL)GLYCINE
Systematic Name English
GLYCINE, N-((3.ALPHA.,5.BETA.,7.BETA.)-3,7-DIHYDROXY-24-OXOCHOLAN-24-YL)-
Systematic Name English
GLYCYLURSODEOXYCHOLIC ACID
Common Name English
URSODEOXYCHOLYLGLYCINE, (+)-
Common Name English
Code System Code Type Description
CHEBI
89929
Created by admin on Sat Dec 16 09:30:00 GMT 2023 , Edited by admin on Sat Dec 16 09:30:00 GMT 2023
PRIMARY
PUBCHEM
12310288
Created by admin on Sat Dec 16 09:30:00 GMT 2023 , Edited by admin on Sat Dec 16 09:30:00 GMT 2023
PRIMARY
FDA UNII
PF1G5J2X2A
Created by admin on Sat Dec 16 09:30:00 GMT 2023 , Edited by admin on Sat Dec 16 09:30:00 GMT 2023
PRIMARY
EPA CompTox
DTXSID20862344
Created by admin on Sat Dec 16 09:30:00 GMT 2023 , Edited by admin on Sat Dec 16 09:30:00 GMT 2023
PRIMARY
CAS
64480-66-6
Created by admin on Sat Dec 16 09:30:00 GMT 2023 , Edited by admin on Sat Dec 16 09:30:00 GMT 2023
PRIMARY
Related Record Type Details
Structure of URSODEOXYCHOLYLGLYCINE SODIUM
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of GLYCOURSODEOXYCHOLIC ACID 3-SULFATE
METABOLITE -> PARENT
Unit: ng/mg creatinine; healthy volunteers (n=12)
IN-VIVO
URINE
Structure of SULFOLITHOCHOLYLGLYCINE
METABOLITE -> PARENT
IN-VIVO
FECAL
Structure of NUTRIACHOLIC ACID
METABOLITE -> PARENT
Unit: percent of total bile acids; Daily dose of UDCA: 1g (n=3); Duration: 2 weeks
IN-VIVO
FECAL
Structure of LITHOCHOLIC ACID
METABOLITE TOXIC -> PARENT
IN-VIVO
FECAL
Structure of URSODIOL
PARENT -> METABOLITE
MAJOR
PLASMA
Structure of URSODEOXYCHOLIC ACID 3-O-.BETA.-D-GLUCOPYRANOSIDURONIDE
METABOLITE -> PARENT
IN-VITRO
Scientific Literature
Structure of URSODEOXYCHOLIC ACID 3-O-.BETA.-D-GLUCOPYRANOSIDURONIDE
METABOLITE -> PARENT
IN-VIVO
URINE
Structure of SULFOLITHOCHOLIC ACID
METABOLITE -> PARENT
LCA-sulfate in serum of gallstone patients given UDCA (n=7; 750mg/day [250mg in the morning, 500mg in the evening] for 2 to 3 weeks); Control (n=5): 0.1 micromole/L
IN-VIVO
PLASMA
Structure of N-ACETYLGLUCOSAMINYL URSODEOXYCHOLYL GLYCINE
METABOLITE -> PARENT
IN-VIVO
URINE
Structure of URSODIOL
METABOLITE ACTIVE -> PARENT
IN-VIVO
URINE
Structure of SULFOLITHOCHOLIC ACID
METABOLITE -> PARENT
Unit: micromole/24hr (baseline: 0.12 mcmol/24hr); Excretion of LCA-sulfate on day 10 of daily oral administration of 750mg UDCA to healthy volunteers
IN-VIVO
URINE
Structure of URSODEOXYCHOLIC ACID GLUCOSIDE
METABOLITE -> PARENT
IN-VIVO
URINE
Structure of SULFOLITHOCHOLIC ACID
METABOLITE -> PARENT
Unit: micromole/g creatinine; LCA-sulfate in urine of gallstone patients given UDCA (n=6; 750mg/day [250mg in the morning, 500mg in the evening] for 2 to 3 weeks); Control (n=6): 0.4 micromole/g creatinine
IN-VIVO
URINE
Structure of SULFOLITHOCHOLIC ACID
METABOLITE -> PARENT
IN-VIVO
FECAL
Structure of LITHOCHOLIC ACID
METABOLITE TOXIC -> PARENT
IN-VIVO
FECAL
Structure of N-ACETYLGLUCOSAMINYL URSODEOXYCHOLIC ACID
METABOLITE -> PARENT
IN-VIVO
URINE
Structure of LITHOCHOLIC ACID
METABOLITE TOXIC -> PARENT
IN-VIVO
FECAL
Structure of URSODEOXYCHOLIC ACID 3-SULFATE
METABOLITE -> PARENT
IN-VIVO
URINE
Structure of URSODEOXYCHOLIC ACID GLUCOSIDE
METABOLITE -> PARENT
IN-VITRO
Scientific Literature
Structure of NUTRIACHOLIC ACID
METABOLITE -> PARENT
Unit: percent of total bile acids; Daily dose of UDCA: 15mg/kg (n=6); Duration: 15 days; before treatment (7-KLCA in feces): 1 % of total bile acids
IN-VIVO
FECAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966